Vemurafenib (ZELBORAF, Hoffmann-La Roche Inc; Figure 1) is a first-in-class selective inhibitor of the BRAF serine-threonine kinase, FDA approved for the treatment of metastatic melanoma harboring ...

a melanoma researcher at the University of Pittsburgh. “We finally have a randomized controlled trial that is positive.” Finalized phase 1 results of a BRAF inhibitor, developed by the ...

Doctors treat melanoma that can be removed with surgery (resectable ... These are called cancer growth blockers or inhibitors. You usually have a BRAF protein inhibitor with a MEK protein inhibitor.

The researchers loaded the platform with two pairs of drugs approved by the FDA: BRAF and MEK inhibitors used to treat melanoma (skin cancer) with a BRAF gene mutation (present in 50% of melanoma ...

This helped pharmaceutical companies develop selective inhibitors of mutated BRAF – including vemurafenib and dabrafenib, which have been approved to treat melanoma. These treatments are frequently ...

Patients with melanoma and colorectal cancer ... currently investigating the possibility of BRAF degraders since BRAF/MEK inhibitor combinations are being utilized to treat a variety of cancer ...

BRAF, a member of a serine/threonine ... currently utilized for the therapy of malignant metastatic melanoma. They include RAF inhibitors, such as sorafenib and vemurafenib, or MEK inhibitors ...

Amtagvi is indicated for intravenous infusion to treat advanced unresectable or metastatic melanoma in ... and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.

This BRAF/CRAF inhibitor is being evaluated in a Phase 3 study called SEACRAFT-2 as part of a combination therapy with Mikinist (trametinib) from Novartis to treat NRASm melanoma. The primary ...

Sometimes the melanoma cannot be removed ... They are called cancer growth blockers or inhibitors. You usually have a BRAF protein inhibitor with a MEK protein inhibitor as they work better together.